Search

Halozyme Therapeutics Inc

Открыт

СекторЗдравоохранение

83.13 0.17

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

82.59

Макс.

84.3

Ключевые показатели

By Trading Economics

Доход

292M

150M

Продажи

-75M

377M

P/E

Средняя по отрасли

28.867

68.51

Прибыль на акцию

1.221

Рентабельность продаж

39.832

Сотрудники

423

EBITDA

-62M

220M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

-2.68% downside

Дивиденды

By Acuity

Следующий отчет о доходах

6 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.1B

9.8B

Предыдущая цена открытия

82.96

Предыдущая цена закрытия

83.13

Новостные настроения

By Acuity

6%

94%

5 / 340 Рейтинг в Healthcare

Halozyme Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 19:22 UTC

News

Halozyme Therapeutics is higher today, driven by 39.1% revenue growth from its ENHANZE technology, which enhances market share and earnings performance.

3 авг. 2026 г., 19:46 UTC

Halozyme Therapeutics Inc. shares are lower today, despite earlier gains, amid a broader market rally following a significant drop in oil prices.

31 июл. 2026 г., 20:06 UTC

Shares of Halozyme Therapeutics are lower today, reflecting broader market trends amid rising U.S. Treasury yields and crude oil prices influencing inflation concerns.

30 июл. 2026 г., 19:58 UTC

Halozyme Therapeutics Inc shares are higher, reflecting a broader recovery in technology stocks amid improved market sentiment. The stock remains near its one-month range.

29 июл. 2026 г., 19:27 UTC

Social Media

Halozyme shares are higher today, despite earlier pulling back. Recent commentary raises concerns about future performance and potential writedowns from acquisitions.

28 июл. 2026 г., 20:03 UTC

Halozyme Therapeutics Inc. is trading higher, benefiting from a broader upward trend in biotechnology stocks, despite a pullback earlier in the session.

27 июл. 2026 г., 19:46 UTC

Shares of Halozyme Therapeutics Inc. are lower today, continuing a decline since Friday. Broader market sentiment is affected by a drop in crude oil prices.

24 июл. 2026 г., 20:07 UTC

News

Halozyme Therapeutics is gaining traction as shares rise, supported by strong cash flow margins and revenue growth. The stock is currently priced at $80.60 per share.

22 июл. 2026 г., 19:35 UTC

Halozyme Therapeutics shares are lower today, despite an earlier peak gain. The decline follows a drop since Tuesday's close amid rising crude oil prices.

Сравнение c конкурентами

Изменение цены

Halozyme Therapeutics Inc Прогноз

Целевая цена

By TipRanks

-2.68% падение

Прогноз на 12 месяцев

Средняя 81 USD  -2.68%

Максимум 96 USD

Минимум 57 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Halozyme Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

3

Покупка

2

Удержание

1

Продажа

Настроения

By Acuity

5 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat